HK1256633A1 - 非晶奧那司酮組合物及其製備方法 - Google Patents
非晶奧那司酮組合物及其製備方法Info
- Publication number
- HK1256633A1 HK1256633A1 HK18115767.9A HK18115767A HK1256633A1 HK 1256633 A1 HK1256633 A1 HK 1256633A1 HK 18115767 A HK18115767 A HK 18115767A HK 1256633 A1 HK1256633 A1 HK 1256633A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- making
- methods
- same
- amorphous onapristone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562267540P | 2015-12-15 | 2015-12-15 | |
PCT/US2016/066420 WO2017106214A1 (en) | 2015-12-15 | 2016-12-13 | Amorphous onapristone compositions and methods of making the same |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1256633A1 true HK1256633A1 (zh) | 2019-09-27 |
Family
ID=59057809
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18114258.8A HK1255104A1 (zh) | 2015-12-15 | 2018-11-08 | 無定形的奧那司酮組合物及其製備方法 |
HK18115767.9A HK1256633A1 (zh) | 2015-12-15 | 2018-12-10 | 非晶奧那司酮組合物及其製備方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18114258.8A HK1255104A1 (zh) | 2015-12-15 | 2018-11-08 | 無定形的奧那司酮組合物及其製備方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US10548905B2 (zh) |
EP (1) | EP3389632A4 (zh) |
JP (1) | JP2019503353A (zh) |
KR (1) | KR20180113988A (zh) |
CN (1) | CN108883067B (zh) |
AU (1) | AU2016370499B2 (zh) |
CA (1) | CA3008422A1 (zh) |
HK (2) | HK1255104A1 (zh) |
MX (1) | MX2018007154A (zh) |
WO (1) | WO2017106214A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3247362A4 (en) | 2014-11-17 | 2018-10-10 | Context Biopharma Inc. | Onapristone extended-release compositions and methods |
AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
KR20180113988A (ko) | 2015-12-15 | 2018-10-17 | 컨텍스트 바이오파마 인코포레이티드 | 비정질 오나프리스톤 조성물 및 그 제조방법 |
WO2018102369A1 (en) | 2016-11-30 | 2018-06-07 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
WO2023172909A1 (en) * | 2022-03-08 | 2023-09-14 | Context Biopharma Inc. | Compositions comprising anti-progestins and selective estrogen receptor modulators and methods of using the same |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8502612A1 (es) * | 1983-06-15 | 1985-02-01 | Schering Ag | Procedimiento para la preparacion de 13a-alquilgonanos |
US4780461A (en) | 1983-06-15 | 1988-10-25 | Schering Aktiengesellschaft | 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same |
DE3321826A1 (de) | 1983-06-15 | 1984-12-20 | Schering AG, 1000 Berlin und 4709 Bergkamen | 13(alpha)-alkylgonane, deren herstellung und diese enthaltende pharmazeutische praeparate |
US4742000A (en) | 1986-05-02 | 1988-05-03 | University Of Chicago | Antibody to human progesterone receptor and diagnostic materials and methods |
DE3630030A1 (de) | 1986-09-01 | 1988-03-03 | Schering Ag | 13(alpha)-alkylgonan-(delta)(pfeil hoch)9(pfeil hoch)(pfeil hoch)((pfeil hoch)(pfeil hoch)1(pfeil hoch)1(pfeil hoch))(pfeil hoch)-5,10-epoxide |
US4774236A (en) | 1986-09-17 | 1988-09-27 | Research Triangle Institute | 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them |
IE60780B1 (en) | 1987-01-23 | 1994-08-10 | Akzo Nv | New 11-aryl steroid derivatives |
DE3822770A1 (de) | 1988-07-01 | 1990-01-04 | Schering Ag | 13-alkyl-11ss-phenylgonane |
US5283190A (en) | 1989-07-31 | 1994-02-01 | Traish Adbulmaged M | Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use |
DE4008584A1 (de) | 1990-03-15 | 1991-09-26 | Schering Ag | Verfahren zur herstellung von zwischenprodukten fuer die antigestagensynthese (onapristonsynthese) |
US5141961A (en) | 1991-06-27 | 1992-08-25 | Richrdson-Vicks Inc. | Process for solubilizing difficulty soluble pharmaceutical actives |
MX9301121A (es) | 1992-03-02 | 1993-09-01 | Schering Ag | Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina. |
CN1053450C (zh) | 1992-11-19 | 2000-06-14 | 北京第三制药厂 | 17位取代11β-取代芳香基-4,9-雌甾二烯类化合物的全合成法 |
DE4332283A1 (de) | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
JPH10507461A (ja) | 1994-10-24 | 1998-07-21 | シエーリング アクチエンゲゼルシヤフト | 必要に応じて女性の稔性を調節するための競合的プロゲステロン拮抗物質 |
US5759577A (en) | 1995-01-17 | 1998-06-02 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US6900193B1 (en) | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
IL122740A (en) | 1997-01-15 | 2003-09-17 | Akzo Nobel Nv | 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them |
US5962444A (en) | 1998-05-29 | 1999-10-05 | Research Triangle Institute | 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
US6537584B1 (en) | 1999-11-12 | 2003-03-25 | Macromed, Inc. | Polymer blends that swell in an acidic environment and deswell in a basic environment |
ATE441433T1 (de) | 2000-05-19 | 2009-09-15 | Genentech Inc | Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine krebstherapie mit einem erbb- antagonisten |
US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
UY26966A1 (es) | 2000-10-18 | 2002-06-20 | Schering Ag | Uso de antiprogestinas para la inducción de apoptosis en una célula |
US7381976B2 (en) | 2001-03-13 | 2008-06-03 | Triton Thalassic Technologies, Inc. | Monochromatic fluid treatment systems |
US7105642B2 (en) | 2001-08-03 | 2006-09-12 | Cell Signalling Technology, Inc. | Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof |
US20040121304A1 (en) | 2001-12-21 | 2004-06-24 | Ulrike Fuhrmann | Method for screening for progesterone receptor isoform-specific ligands and for tissue-selective progesterone receptor ligands |
WO2004078709A2 (en) | 2003-02-28 | 2004-09-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | METHOD FOR PREPARING 17 α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES THEREOF, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES |
US20040265371A1 (en) | 2003-06-25 | 2004-12-30 | Looney Dwayne Lee | Hemostatic devices and methods of making same |
BRPI0513141A (pt) | 2004-07-09 | 2008-04-29 | Population Council Inc | composição para anel vaginal, e, processo de contracepção a longo prazo |
EP1800130B1 (en) | 2004-09-22 | 2011-08-17 | Tripath Imaging, Inc. | Methods and compositions for evaluating breast cancer prognosis |
WO2006111856A1 (en) | 2005-04-20 | 2006-10-26 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
JP2009519710A (ja) | 2005-12-16 | 2009-05-21 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 遺伝子発現調節エレメントのハイスループットでの特徴付けのための機能性アレイ |
US20070167971A1 (en) | 2006-01-17 | 2007-07-19 | Raymond Huey | Devices and methods for promoting the formation of blood clots in esophageal varices |
US20070166372A1 (en) | 2006-01-19 | 2007-07-19 | Mai De Ltd. | Preparation of solid coprecipitates of amorphous valsartan |
PL1989217T4 (pl) | 2006-02-17 | 2013-02-28 | Janssen Pharmaceutica Nv | 11-fosforowe pochodne steroidowe użyteczne jako modulatory receptora progesteronu |
DE102006054535A1 (de) | 2006-11-15 | 2008-05-21 | Bayer Schering Pharma Aktiengesellschaft | Progesteronrezeptorantagonisten |
CN101668739A (zh) | 2007-04-24 | 2010-03-10 | 帝斯曼知识产权资产管理有限公司 | 用于制造前维生素d的光化学方法 |
CA2596204C (en) | 2007-08-07 | 2019-02-26 | Historx, Inc. | Method and system for determining an optimal dilution of a reagent |
EP2075246A1 (en) * | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
WO2009100258A1 (en) | 2008-02-05 | 2009-08-13 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical solid state forms |
TW201002736A (en) | 2008-04-28 | 2010-01-16 | Repros Therapeutics Inc | Compositions and methods for treating progesterone-dependent conditions |
TWI539953B (zh) | 2008-04-28 | 2016-07-01 | 瑞波若斯治療學公司 | 用於治療乳癌之組成物和方法 |
EP2412662A4 (en) | 2009-03-27 | 2017-03-29 | Komatsu Ltd. | Fuel saving control device for working machine and fuel saving control method for working machine |
US20110003753A1 (en) | 2009-06-01 | 2011-01-06 | Samuel Waxman Cancer Research Foundation | COMPOSITIONS AND METHODS FOR DISRUPTING THE FUNCTION OF THE TRANSCRIPTIONAL REPRESSOR COMPONENT Sin3A-PAH2 DOMAIN TO INDUCE DIFFERENTIATION AND GROWTH INHIBITION IN BREAST CANCER |
RU2543721C2 (ru) | 2009-07-15 | 2015-03-10 | СиТиАй БИОФАРМА КОРП. | Цитратная соль 9е-15-(2-пирролидин-1-ил-этокси)-7,12,25-триокса-19,21,24-триазатетрацикло[18.3.1.1(2,5).1(14,18)]гексакоза-1(24),2,4,9,14,16,18(26),20,22-нонаена |
US20110293511A1 (en) | 2009-09-29 | 2011-12-01 | Terrance Grant Johns | Specific binding proteins and uses thereof |
US9295649B2 (en) * | 2009-12-15 | 2016-03-29 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
JP5894143B2 (ja) | 2010-03-22 | 2016-03-23 | リプロス セラピューティクス インコーポレイテッド | 抗黄体ホルモンの無毒送達のための組成物および方法 |
EP3702460A1 (en) | 2010-11-12 | 2020-09-02 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
CA2821805A1 (en) | 2010-12-16 | 2012-06-21 | Celgene Corporation | Controlled release oral dosage forms of poorly soluble drugs and uses thereof |
CA2822462A1 (en) | 2010-12-20 | 2012-06-28 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
EP2683737A4 (en) | 2011-03-09 | 2014-09-03 | Ct Se Llc | EXTRACELLULAR TARGETED CONSTITUENT CONJUGATES |
US20140148473A1 (en) | 2011-03-11 | 2014-05-29 | Celgene Corporation | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases |
EP2698634B1 (en) | 2011-04-15 | 2017-11-08 | J-Pharma Co., Ltd. | Biomarker for breast cancer |
US20130029953A1 (en) | 2011-07-28 | 2013-01-31 | Klaus Nickisch | Progesterone antagonists |
RU2672874C2 (ru) | 2011-10-04 | 2018-11-20 | Инвайвис Фармасьютикалз Инк. | Способы и системы для выявления и лечения опухолей, восприимчивых к антипрогестинам |
MX2014006820A (es) | 2011-12-08 | 2015-05-11 | Fundacion Sales | Metodos y composiciones para tratar canceres resistentes a antiprogestina. |
US20130338016A1 (en) | 2012-04-17 | 2013-12-19 | Vala Sciences, Inc. | Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis |
KR20150028232A (ko) | 2012-04-27 | 2015-03-13 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 프로게스테론 수용체 서브타입의 유방암 예후, 예측 및 유전자 발현을 토대로 한 항프로게스틴 치료에 대한 반응성 예측 방법 |
AU2013295815A1 (en) | 2012-07-24 | 2015-02-05 | Cedars-Sinai Medical Center | A novel method to detect resistance to chemotherapy in patients with lung cancer |
AU2013358968B2 (en) | 2012-12-13 | 2017-12-21 | Warsaw Orthopedic, Inc. | Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury |
CA2904116C (en) * | 2013-03-12 | 2021-09-14 | Arno Therapeutics | Onapristone polymorphic forms and methods of use |
US20140363425A1 (en) | 2013-03-13 | 2014-12-11 | J. Dinny Graham | Systems and methods for identifying cancers having activated progesterone receptors |
US9096641B2 (en) | 2013-06-05 | 2015-08-04 | Evestra, Inc. | Imidazolyl progesterone antagonists |
CN106170701A (zh) | 2014-04-08 | 2016-11-30 | 阿尔诺治疗公司 | 用于鉴定孕酮受体亚型的系统及方法 |
EP3247362A4 (en) | 2014-11-17 | 2018-10-10 | Context Biopharma Inc. | Onapristone extended-release compositions and methods |
US10053485B2 (en) | 2015-03-23 | 2018-08-21 | Evestra, Inc. | Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents |
AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
KR20180113988A (ko) | 2015-12-15 | 2018-10-17 | 컨텍스트 바이오파마 인코포레이티드 | 비정질 오나프리스톤 조성물 및 그 제조방법 |
US20170266204A1 (en) | 2016-03-21 | 2017-09-21 | Arno Therapeutics, Inc. | Onapristone metabolite compositions and methods |
-
2016
- 2016-12-13 KR KR1020187019175A patent/KR20180113988A/ko not_active Application Discontinuation
- 2016-12-13 MX MX2018007154A patent/MX2018007154A/es unknown
- 2016-12-13 WO PCT/US2016/066420 patent/WO2017106214A1/en active Application Filing
- 2016-12-13 CN CN201680077010.2A patent/CN108883067B/zh active Active
- 2016-12-13 CA CA3008422A patent/CA3008422A1/en active Pending
- 2016-12-13 JP JP2018532190A patent/JP2019503353A/ja active Pending
- 2016-12-13 AU AU2016370499A patent/AU2016370499B2/en not_active Ceased
- 2016-12-13 US US15/378,004 patent/US10548905B2/en not_active Expired - Fee Related
- 2016-12-13 EP EP16876503.0A patent/EP3389632A4/en not_active Withdrawn
-
2018
- 2018-11-08 HK HK18114258.8A patent/HK1255104A1/zh unknown
- 2018-12-10 HK HK18115767.9A patent/HK1256633A1/zh unknown
-
2019
- 2019-12-19 US US16/720,425 patent/US20200376004A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN108883067B (zh) | 2021-03-09 |
US20170182065A1 (en) | 2017-06-29 |
CA3008422A1 (en) | 2017-06-22 |
US10548905B2 (en) | 2020-02-04 |
US20200376004A1 (en) | 2020-12-03 |
EP3389632A4 (en) | 2019-11-06 |
KR20180113988A (ko) | 2018-10-17 |
CN108883067A (zh) | 2018-11-23 |
HK1255104A1 (zh) | 2019-08-02 |
WO2017106214A1 (en) | 2017-06-22 |
AU2016370499A1 (en) | 2018-07-12 |
JP2019503353A (ja) | 2019-02-07 |
EP3389632A1 (en) | 2018-10-24 |
AU2016370499B2 (en) | 2022-06-30 |
MX2018007154A (es) | 2019-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192145T1 (hr) | Pripravci nosača-antitijela i metode pripreme i uporabe istih | |
HK1256726A1 (zh) | 載體結合劑組合物及其製備和使用方法 | |
IL268970A (en) | New preparations and methods | |
HK1214171A1 (zh) | 賽尼克韋羅組合物及其製備和使用方法 | |
HUE065174T2 (hu) | HLA-alapú módszerek és készítmények, valamint azok felhasználása | |
GB201807325D0 (en) | Compositions and methods | |
EP3166892A4 (en) | Scale-inhibition compositions and methods of making and using the same | |
ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
GB202201861D0 (en) | Novel methods and compositions | |
HK1256633A1 (zh) | 非晶奧那司酮組合物及其製備方法 | |
PL3560558T3 (pl) | Kompozycje nawozów oraz sposoby ich wytwarzania i stosowania | |
IL268570B (en) | Oligonucleotide preparations and methods for their preparation | |
HK1247136A1 (zh) | 包含15-hepe的組合物和其使用方法 | |
HK1246653A1 (zh) | 奧那司酮延長釋放組合物和方法 | |
PT3113774T (pt) | Composições de grapiprant e métodos de utilização das mesmas | |
ZA202004533B (en) | Skin-brightening compositions and methods | |
GB201705626D0 (en) | Compositions and methods | |
ZA201807665B (en) | Methods and compositions | |
GB201715820D0 (en) | Compositions and methods | |
ZA201807782B (en) | Methods and compositions | |
GB201704298D0 (en) | Compositions and methods |